{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:34:50Z","timestamp":1791909290365,"version":"4.3.4"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T00:00:00Z","timestamp":1669766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Acute myeloid leukemia (AML) is a form of cancer that is characterized by infiltration of the bone marrow, blood, and other tissues by proliferative, clonal, abnormally differentiated, and occasionally poorly differentiated cells of the hematopoietic system. Patients with acute myeloid leukemia (AML) receiving azacitidine (AZA) alone or in combination with venetoclax (VEN-AZA) are at increased risk for invasive fungal infections (IFIs). We compared the incidence and risk of IFI during these treatment regimens in a single Taiwan hospital.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>A total of 61 patients with AML received at least one course of AZA in the hematology ward of China Medical University Hospital (Taichung, Taiwan) between September 2012 and June 2020. Thirty-eight patients (62.3%) received AZA monotherapy; 23 (37.7%) received VEN-AZA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Incidence rates of probable and proven IFI were 18% and 1.6%, respectively, during AZA treatment. One proven case of <jats:italic>Fusarium<\/jats:italic> spp. infection was isolated by skin and soft tissue culture. Most (75%) IFI cases occurred during the first cycle of AZA therapy. Half of all IFI cases occurred in patients with prolonged neutropenia. The risk of IFI was significantly higher for the European LeukemiaNet (ELN) nonfavorable-risk group (intermediate- and adverse-risk group) versus the ELN favorable-risk group and for patients with prolonged neutropenia versus those without (<jats:italic>P<\/jats:italic>&amp;lt;0.05 for both comparisons). In this study, median OS did not differ significantly between patients with and without IFIs during AZA-containing regimens (14.6 months vs 13.7 months; <jats:italic>P<\/jats:italic>=0.59).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The incidence of IFI was high in this AML cohort treated with AZA-containing regiments in Taiwan. The majority of IFI cases occurred during the early cycles of AZA (cycles 1\u20132). Prospective studies are needed to determine the optimal choice of antifungal prophylaxis agent during VEN-AZA therapy for AML. <\/jats:p><\/jats:sec>","DOI":"10.3389\/fcimb.2022.1012334","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T06:55:48Z","timestamp":1669791348000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["High rate of invasive fungal infections during early cycles of azacitidine for patients with acute myeloid leukemia"],"prefix":"10.3389","volume":"12","author":[{"given":"Sing-Ting","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Huei","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Ting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Chan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Yuan","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Peng","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao-Wang","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Yu","family":"Lien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.clinthera.2017.01.003","article-title":"Management of venetoclax-posaconazole interaction in acute myeloid leukemia patients: Evaluation of dose adjustments","volume":"39","author":"Agarwal","year":"2017","journal-title":"Clin. Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1182\/bloodadvances.2019000930","article-title":"Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents","volume":"3","author":"Aldoss","year":"2019","journal-title":"Blood Adv."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1002\/cam4.1231","article-title":"Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen","volume":"6","author":"Ali","year":"2017","journal-title":"Cancer Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1182\/bloodadvances.2019000792","article-title":"Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival","volume":"4","author":"Br\u00fcck","year":"2020","journal-title":"Blood Adv."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/myc.13147","article-title":"Impact of invasive aspergillosis occurring during first induction therapy on outcome of acute myeloid leukaemia (SEIFEM-12B study)","volume":"63","author":"Candoni","year":"2020","journal-title":"Mycoses"},{"key":"B6","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/cpdd.395","article-title":"Pharmacokinetics of the BCL-2 inhibitor venetoclax in healthy Chinese subjects","volume":"7","author":"Cheung","year":"2018","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"B7","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl. J. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cellimm.2017.10.002","article-title":"Exhaustion of T lymphocytes in the tumor microenvironment: Significance and effective mechanisms","volume":"322","author":"Davoodzadeh Gholami","year":"2017","journal-title":"Cell Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e441","DOI":"10.1038\/bcj.2016.50","article-title":"'Acute myeloid leukemia: a comprehensive review and 2016 update'","volume":"6","author":"De Kouchkovsky","year":"2016","journal-title":"Blood Cancer J."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1093\/jac\/dky550","article-title":"'Real-life' analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza epidemiologica infezioni nelle emopatie (SEIFEM) 2016 study","volume":"74","author":"Del Principe","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European organization for research and treatment of Cancer\/Invasive fungal infections cooperative group and the national institute of allergy and infectious diseases mycoses study group (EORTC\/MSG) consensus group","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl. J. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N Engl. J. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1002\/ajh.25975","article-title":"Acute myeloid leukemia: 2021 update on risk-stratification and management","volume":"95","author":"Estey","year":"2020","journal-title":"Am. J. Hematol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.clml.2013.09.014","article-title":"Patterns of infection in patients with myelodysplastic syndromes and acute myeloid leukemia receiving azacitidine as salvage therapy. implications for primary antifungal prophylaxis","volume":"14","author":"Falantes","year":"2014","journal-title":"Clin. Lymphoma Myeloma Leuk"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000011860","article-title":"Incidence and risk of hematologic toxicities with hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukopenia: A systematic review and meta-analysis","volume":"97","author":"Gao","year":"2018","journal-title":"Med. (Baltimore)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s00277-021-04716-4","article-title":"ELN 2017 classification significantly impacts the risk of early death in acute myeloid leukemia patients receiving intensive induction chemotherapy","volume":"101","author":"Keren-Froim","year":"2022","journal-title":"Ann. Hematol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1002\/ajh.25808","article-title":"Risk of invasive fungal infections in patients with high-risk MDS and AML receiving hypomethylating agents","volume":"95","author":"Kim","year":"2020","journal-title":"Am. J. Hematol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jmii.2017.07.006","article-title":"2016 guidelines for the use of antifungal agents in patients with invasive fungal diseases in Taiwan","volume":"51","author":"Kung","year":"2018","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"B23","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/hon.2710","article-title":"Pulmonary infections in patients with myelodysplastic syndromes receiving frontline azacytidine treatment","volume":"38","author":"Latagliata","year":"2020","journal-title":"Hematol. Oncol."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0197851","article-title":"Epidemiology and risk factors for invasive fungal infections during induction chemotherapy for newly diagnosed acute myeloid leukemia: A retrospective cohort study","volume":"13","author":"Lien","year":"2018","journal-title":"PloS One"},{"key":"B25","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jmii.2016.08.011","article-title":"Clinical characteristics and outcome of invasive fungal infections in pediatric acute myeloid leukemia patients in a medical center in Taiwan","volume":"51","author":"Lin","year":"2018","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"B26","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.clml.2019.01.002","article-title":"Predictive model for infection risk in myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia patients treated with azacitidine; azacitidine infection risk model: The polish adult leukemia group study","volume":"19","author":"M\u0105dry","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk"},{"key":"B27","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.1093\/jac\/dky286","article-title":"European Guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European conference on infections in leukaemia","volume":"73","author":"Maertens","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"B28","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/leu.2013.176","article-title":"Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: A report from SWOG and MD Anderson","volume":"28","author":"Othus","year":"2014","journal-title":"Leukemia"},{"key":"B29","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/myc.12500","article-title":"Invasive fungal infections in AML\/MDS patients treated with azacitidine: a risk worth considering antifungal prophylaxis","volume":"59","author":"Pomares","year":"2016","journal-title":"Mycoses"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1158\/1078-0432.Ccr-19-3003","article-title":"Characterization of immune dysfunction and identification of prognostic immune-related risk factors in acute myeloid leukemia","volume":"26","author":"Tang","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1200\/jco.18.00374","article-title":"Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/ejh.13631","article-title":"Risk factors for invasive fungal infection in 5-azacytidine treated patients with acute myeloid leukemia and myelodysplastic syndrome","volume":"107","author":"Tey","year":"2021","journal-title":"Eur. J. Haematol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1080\/10428194.2017.1295141","article-title":"Incidence, etiology and timing of infections following azacitidine therapy for myelodysplastic syndromes","volume":"58","author":"Trubiano","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1080\/10428194.2021.1891230","article-title":"Decitabine combined with low dose idarubicin and cytarabine (D-IA) followed by allo-HSCT improves acute myeloid leukemia and higher-risk myelodysplastic syndrome patient outcomes: results from a retrospective study","volume":"62","author":"Xu","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"B35","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jmii.2015.05.020","article-title":"Burden of invasive mold disease in patients with acute myelogenous leukemia and in stem cell transplant recipients","volume":"50","author":"Yang","year":"2017","journal-title":"J. Microbiol. Immunol. Infect."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2022.1012334\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T06:55:50Z","timestamp":1669791350000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2022.1012334\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,30]]},"references-count":35,"alternative-id":["10.3389\/fcimb.2022.1012334"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2022.1012334","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,30]]},"article-number":"1012334"}}